Tag Archives: watchdogs

Novartis slaps $2M-plus price tag on newly approved gene therapy Zolgensma—and cost watchdogs approve

Industry watchers have been speculating for months about just how high Novartis would price gene therapy Zolgensma on approval—and just how payers would cover it. And with the FDA’s green light, they now have an answer. The Swiss drugmaker will roll out the drug, a one-time treatment for pediatric patients less than 2 years of… Read More »

Roche’s Tecentriq-Avastin lung cancer combo gets a lift from England’s cost watchdogs

Roche has some hard-earned knowledge about working with England’s cost watchdogs, especially where its cancer drugs are concerned. And it put that know-how to use to score backing for Tecentriq in lung cancer. The National Institute of Health and Care Excellence (NICE) decided to back the immuno-oncology drug, in combination with Roche’s Avastin and chemo,… Read More »